Spiriva Respimat is now available in US pharmacies for the treatment of asthma, Boehringer Ingelheim has announced. The FDA approved Spiriva Respimat for the treatment of asthma in patients aged 12 and older in September 2015.
The tiotropium bromide soft mist inhaler was approved by the FDA for the treatment of COPD in September 2014 and has been available in the US for that indication since January 2015.
According to the company, Spiriva Respimat is covered by the majority of US insurance plans with “favorable” formulary access for both indications. BI is also offering patients a savings card to cover 12 months of treatment.
Boehringer Ingelheim Pharmaceuticals VP, Respiratory Marketing, Clare Burrows commented, “As an industry leader in respiratory, Boehringer Ingelheim is committed to addressing unmet needs and to improving patient care for those with serious respiratory diseases, such as asthma. The approval of Spiriva Respimat marks our entrance into the asthma space and we are proud to offer a new approach for healthcare providers and patients to consider for the treatment of asthma.”
Read the Boehringer Ingelheim press release.
